Streamex Corp. · NASDAQ:STEX
Streamex — BioSig Technologies — Investor Presentation (November 2020)
20 slides from Streamex's investor presentation, Nov 6, 2020
Slide 1: BioSig Technologies Investor Presentation Fall 2020
BioSig technologies™ Evrcne Presentatio 1 Fall 2020 NASDAQ: BSGM
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new pr
Slide 3: BioSig Technologies Positioned for Success
BioSig Technologies Positioned for Success -—® Demand driven by high prevalence of arrhythmia ____@ Procedures more efficacious than drugs, predicated on ability to analyze clean cardiac signals ;-® Differentiated value proposition and impact to the patient -——® Current standard of care negatively a
Slide 4: Seasoned Management Team, Possessing the Necessary Skillset and Knowledge to Drive Commercialization
Seasoned Management Team, Possessing the Necessary Skillset and Knowledge to Drive Commercialization Kenneth L. Londoner, MBA Founder, Chairman, CEO, Director NeuroGiear Technologles; Endicott Management Partners; J&A Seligman & Co, Steve Chaussy, CPA Fo Neurotiear Technologies; Lierski Inc; Anna &C
Slide 5: Defining the Market Opportunity
Defining the Market Opportunity Global Growth in EP Devices: $4.5B in 2017, projected to reach $7.4B in 2022 10.4% growth rate Global Growth ous: in Complex Cardiac Ablation 3,729 hospitals averaging Procedures: 1.05 rooms per lab 440,629 in 2017 to 830,390 in 2022 3,915 13.5% growth rate . EP room
Slide 6: Electrophysiology Market Overview
Electrophysiology Market Overview Consistent, long-term growth is driven by demographic trends and clinical evidence (ablation vs. drug therapy) Key Market Players Global Market Share for Catheter Ablation Devices Others ‘Access Devices BioSenee Abbott 32% Source: B. CC: Research (2018, November). A
Slide 7: As Hospitals Resume Elective Procedures, Should they Prioritize Electrophysiology During COVID-19?
As Hospitals Resume Elective Procedures, Should they Prioritize Electrophysiology During COVID-19? EP procedures are clinically urgent Reimbursement rates continue to Increase + Delaying procedure increases stroke risk and worsens outcomes * From 2019 to 2020 ablations and LAAO (DRG 274) had a reimb
Slide 8: PURE EP Developed Through Collaboration with Leading Centers
PURE EP™ Developed Through Collaboration with Leading Centers Relationships at leading, high-volume centers create traction for PURE EP™ in the market 20114 2013 2014 2014 2015 2016 EE ee SS Se Se Concept developed Proof of concept Prototype test Initial pre-clinical Firstpre-clinical Advanced resea
Slide 9: Unique Collaboration with Mayo Clinic
Unique Collaboration with Mayo Clinic + 10-year strategic agreement ~ Collaboration on technology development ~ Joint IP filings = Licensing opportunities ~ Mayo Clinic has invested capital in the development of the PURE EP/™ System * First PURE EP™ System installed at Mayo Clinic in Florida in Janu
Slide 10: Our First FDA-Cleared Product - PURE EP System
Our First FDA-Cleared Product - PURE EP™ System: Addressing Unmet Clinical Need of More Reliable ECG Signals PURE EP™ System provides innovative technology that fulfills unmet clinical needs while benefitting patients, physicians, and payors Signal processing platform designed to reveal the full ran
Slide 11: Physician Testimonies
Physician Testimonies i] “The PURE EP System does provide innovative design with greater resolution and greater bandwidth, which should allow for safer and more efficacious ablations in the future.” - K. Venkatachalam, M.D., Cardiac Electrophysiologist, Mayo Clinic Mayo. CLINIC Gy ‘Texas Carpiac ARR
Slide 12: Our Clinical Path
Our Clinical Path PRE-CLINICAL STUDIES * Mayo Clinic, Mount Sinai, University of Pennsylvania + Published peer reviews in leading journals FIRST-IN-HUMAN CASES + 21 patients * TCAl, Greenville Memorial Hospital, University of Indiana + Results shown improved signal fidelity PURE El" SEE MORE, CLEARL
Slide 13: Our Recent PURE EP Study - ESC 2020 EP
Our Recent PURE EP™ Study - ESC 2020 EP SEE MORE, CLEARLY * Ablinded, independent analysis confirmed that the PURE EP™ system's signals are preferred to conventional sources * In 35.5% of samples, the reviewers selected PURE EP™ data because "more signal components were visible“ * PURE EP™ System pr
Slide 14: PURE EP Business Model
PURE EP SEE MORE, CLEARLY + High-value annotated data for further applications + Offers software solutions for clinically validated applications Business Model Service Agreements + Additional revenue from training, installation, ac eS and software upgrades + Foundation of the business model starts w
Slide 15: Presenting PURE EP at Leading Conferences to Boost Awareness and Physician Support
Presenting PURE EP™ at Leading Conferences in Order to Boost Awareness and Physician Support 25th Annual international Svpcsul620 AFIB SYMPOSIUM 2020 JAN 23-25 PLACE: Washington, DC Spotlight Session: Innovation in EP Booth: Dr. Andrea Natale Pr « () Clinical and Ge Technology Demonstration (ii) Tec
Slide 16: Key Milestones
Key Milestones 2020 2021 a J Targeted commercial release of PURE EP™ System Accelerate commercialization of PURE EP™ in U.S. A Clinical data publication and new evidence-based trials File further IP, advance R&D in bioelectronic medicine A Develop new product pipeline to complement PURE EP™ Clinical
Slide 17: Strong IP Strategy, Supported by Experts
Strong IP Strategy, Supported by Experts 31 allowed/issued worldwide design and utility patents, which cover various features of the PURE EP™ System's display screens and graphical user interface for enhanced visualization of biomedical signals Differentiated combination of hardware and software is
Slide 18: EP Sector M&A Activity
EP Sector M&A Activity Proof of Clinical CE Acquirer, j Company Ere Prototype ince Mi FDA Sales pach Valuation BioSig Technologies A 5 = % $102.52 million Formed 2009 Nov 05, 2020 EPD Solutions $563 million Formed 2014 is bs £ : is PHILIPS June 2018 June 2016 fe $80 million Hansen Medical ° ° ° . .
Slide 19: Business Model Summary
Business Model Summary Highlights: Expected to be in ten centers by year-end 2020 PURE EP™ System expected to generate revenue beginning in Q4 2020 Scaling up organization through increasing salesforce and extending relationships with world- class healthcare institutions Robust US-based supply chain
Slide 20: Board of Directors
Board of Directors Kenneth L. Londoner, MBA *. BioSig amass Andrew Filler, JD Donald E. Foley, MBA <> wrmincton Wlaxacourasie M&TBank Tes Patrick J. Gallagher, MBA, CFA “Gneuare — Alfienex Samuel E. Navarro eewremnes pos as Gravitas ee STRATA Healthcare eavironscoup Jeffrey F. O'Donnell, Sr. Trice e
BioSig Technologies — Investor Presentation (November 2020) on 6ix